Heron Therapeutics, Inc. (HRTX) Investor Relations Documents
Heron Therapeutics, Inc. (HRTX) investor relations documents from the company's IR site: 9 presentations, 2 press releases; latest deck 2023-07-30. Read in-app with summaries. First-party data.
Cusick M, Yuan N, Yamamoto A, et al. Safety, Pharmacokinetics, and Analgesia of HTX-011 in Total Shoulder Arthroplasty. Presented at the Southern Orthopedic Association’s (SOA) Annual Meeting, July 26-29, 2023: A Phase 4 study of ZYNRELEF in total shoulder arthroplasty shows it is well-tolerated and reduces opioid consumption compared to bupivacaine HCl.
Investor relations documents — source: company IR site| Published | Type | Document |
|---|
| 2026-04-27 | Press release | Apr 27 2026 - Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday,... |
| 2026-02-26 | Press release | Feb 26 2026 - Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results... |
| 2023-07-30 | Presentation | Cusick M, Yuan N, Yamamoto A, et al. Safety, Pharmacokinetics, and Analgesia of HTX-011 in Total Shoulder Arthroplasty. Presented at the Southern Orthopedic Association’s (SOA) Annual Meeting, July 26-29, 2023 |
| 2022-11-07 | Presentation | John Fanikos, Jackie Evans-Shields, Nancy Yuan, Francesco Palazzo, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; Heron Therapeutics, Inc., San Diego, CA, Jefferson Methodist Hospital, Thomas Jefferson University, Philadelphia, PA. Opioid-Free Recovery after Inguinal Hernia Repair with Bupivacaine and Meloxicam Extended-Release Solution (ERBMS) as the Foundation of a Multimodal Analgesia Regimen in a Real-World Setting . Presented at ASHP Annual Meeting 2022, Las Vegas. |
| 2022-09-21 | Presentation | Amy Yamamoto, Chris Storgard, Nancy Yuan, Thomas Ottoboni. Phase 1 Bioavailability Study of HTX-019 Intravenous Injection Compared with Aprepitant Oral Capsules. Presented at the American Society of Anesthesiology 2022 Meeting, October 21-25, 2022. |
| 2022-04-26 | Presentation | Craig Saffer, Chris Storgard, Katie Luepke, Timothy Melson. Interim Safety and Efficacy of HTX-011 Administered Postpartum to Women Undergoing a Planned Caesarean Section. Presented at the 54th Annual Meeting of the Society for Obstetric Anesthesia and Perinatology, Chicago, IL, May 2022. |
| 2021-10-14 | Presentation | Charles Luke, Francesco Palazzo, Phillip Shadduck, John Fanikos, Jia Hu. Opioid-Free Inguinal Hernia Repair with a Non-Opioid, Multimodal Analgesia (MMA) Regimen Including HTX-011 in a Real-World Setting. Presented at the 2021 ASRA 20th Annual Pain Medicine Meeting, November 18-20 2021. |
| 2021-10-09 | Presentation | Minkowitz H, Luke C, Hardman D, Hu J. Overall Safety Of HTX-011 When Used With Scheduled Non-Opioid NSAID-containing Multimodal Analgesia (MMA). Presented at the American Society of Anesthesiologists Annual Meeting, Oct 9-12, 2021. |
| Presentation | Viscusi E, Onel E, Boccia G, Chu A, Keller MR, Ottoboni T, Patel SS, Cravets M, Manhard K, Quart B. HTX-011, A locally administered analgesic, reduces postoperative pain intensity and opioid use through 72 hours across bony and soft tissue surgical models. Presented at the European Society of Regional Anaesthesia & Pain Therapy (ESRA) 2017 Annual Congress, September 2017. |
| Presentation | Onel E, Chu A, Patel SS, Ottoboni T, Wilker C, Quart B. Synergistic effect of bupivacaine and meloxicam in HTX-011 across multiple doses and surgeries. Presented at ACCP 2017 Annual Meeting, October 2017. |
| Presentation | Viscusi E, Minkowitz H, Onel E, Chu A, Patel SS, Ottoboni T, Wilker C, Quart B. Synergistic Effect of the Active Components in HTX-011, a Novel Fixed-ratio Formulation of Bupivacaine and Meloxicam, Across Multiple Doses and Surgical Models. Presented at ASRA Spring 2018, April 2018. |
HRTX overview · HRTX earnings · HRTX financials · HRTX KPIs · HRTX ownership · HRTX peers · HRTX filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.